Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -87.27.

Financial Results for the Year Ended December 31, 2025

Cash Position

Aptevo Therapeutics Inc. ended 2025 with $21.6 million in cash and cash equivalents, a significant increase from $8.7 million at December 31, 2024 .

Research and Development Expenses

Research and development expenses were $14.5 million for the year ended December 31, 2025, compared to $14.4 million for the year ended December 31, 2024 .

General and Administrative Expenses

General and administrative expenses increased to $11.8 million for the year ended December 31, 2025, up from $10.2 million in 2024 .

Other Income, Net

Other income, net, was $0.3 million for the year ended December 31, 2025, a decrease from $0.5 million in 2024 .

Net Loss Attributable to Common Shareholders

Aptevo Therapeutics Inc. reported a net loss of - $26.0 million for the year ended December 31, 2025, compared to a net loss of - $24.1 million in 2024 . Including a dividend, the net loss attributable to common shareholders for EPS purposes was - $27.5 million in 2025 .

Balance Sheet Highlights (as of December 31, 2025)

Total Current Assets

Total Current Assets were $23.1 million, up from $10.7 million in 2024 .

Total Assets

Total Assets were $27.2 million, up from $15.6 million in 2024 .

Total Current Liabilities

Total Current Liabilities were $6.1 million, down from $6.2 million in 2024 .

Total Liabilities

Total Liabilities were $9.8 million, down from $10.8 million in 2024 .

Total Stockholders’ Equity

Total Stockholders’ Equity was $17.4 million, up from $4.8 million in 2024 .

Operational Metrics (Clinical Performance)

Updated interim results for mipletamig in combination with ven/aza in 28 evaluable frontline AML patients showed an 86% clinical benefit rate, including a 79% CR/CRi remission rate and a 61% complete remission rate . Notably, 55% of patients achieving remission reached measurable residual disease–negative status, and 35% of remissions occurred in patients with TP53 mutations . No cytokine release syndrome has been observed in frontline patients treated to date .

Outlook / Guidance

Aptevo Therapeutics Inc. expects its current resources to support operations into the fourth quarter of 2026 . The company established a $60 million equity line facility in 2026, which, if fully utilized alongside current resources, is expected to support operations into 2029 . This facility provides financing flexibility and allows the company to access capital opportunistically .